Marten MD, Ramírez AMC, Fernández DJ

Language: Spanish
References: 13
Page:
PDF size: 45.78 Kb.

ABSTRACT

At the present time, of all the visceral morbid processes affecting the human being, colorectal cancer is the one causing death more frequently. Taking as base the more and more high incidence of this tumor in the world, and specifically in Santiago de Cuba province, the interest arose in proposing a deeper study of the patients who were positive to tumoral cells in the ureasa test. The objective of this work was to deal important aspects related to the opportune diagnosis of the disease, which requires of the integration of several hospital services, in order to avoid death among those affected.

REFERENCES

1. O'Leary BA, Olynyk JK, Neville AM, Platell CF. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol. 2004; 19(1): 38-7.

2. Vijan S, Hwang EW, Hofer TP, Hayward RA. Which colon cancer screening test? A comparison of costs, effectiveness and compliance. Am J Med. 2001; 111(8): 593- 601.

3. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137(2): 132-41.

4. Lieberman DA, Harford WV, Ahnen DJ, et al. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001; 345(8): 555-60.

5. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality for colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328(19): 1365-71.

6. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy? JAMA. 1994; 271(13): 1011-3.

7. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348(9040): 1492-7.

8. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996; 348(9040): 1467-71.

9. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004; 126(7): 1674-80.

10. 10.Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129(2): 422-8.

11. 11.Kumar V, Cotran Rs, Robbins S. Robbins: Patología estructural y funcional. 6 ed. Madrid: McGraw-Hill Interamericana; 1999. p.

12. 12.Castells Garengou A, Piqué Badia JM. Tumores Intestinales. En: Rozman Borstnar C, Cardellach López F. Farreras-Rozman. Medicina Interna. 14 ed. Barcelona: Elsevier; 2000.

13. 13.Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical fecal occult blood screening test. Am J Gastroenterol. 2005; 100(11): 2519-25.